Biohaven (BHVN) Free Cash Flow (2021 - 2026)
Biohaven (BHVN) posted Free Cash Flow of -$149.9 million for Q1 2026, down 14.73% sequentially from -$130.7 million in Q4 2025, and up 9.46% YoY from -$137.0 million in Q1 2025.
Analysis
Biohaven (BHVN) Free Cash Flow (2021 - 2026) Analysis & Trends
Biohaven has reported Free Cash Flow for 6 years, with the latest figure at -$149.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 9.46% year-over-year to -$149.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$594.5 million (up 8.4% YoY) and the FY2025 annual result came in at -$610.2 million, down 4.03% from the prior year.
- Free Cash Flow slipped to -$149.9 million in Q1 2026 per BHVN's latest filing, from -$130.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$45.0 million in Q2 2023 and troughed at -$170.8 million in Q4 2024.
- A 5-year average of -$116.8 million and a median of -$115.4 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 34.7% in 2023, then tumbled 279.54% in 2024.
- Over 5 years, Free Cash Flow stood at -$75.7 million in 2022, then slumped by 52.37% to -$115.4 million in 2023, then sank by 48.06% to -$170.8 million in 2024, then grew by 23.49% to -$130.7 million in 2025, then declined by 14.73% to -$149.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$149.9 million, -$130.7 million, and -$145.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | -85.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -85.55 Mn |
| Mar 31, 2026 | -149.92 Mn |
| Dec 31, 2025 | -130.67 Mn |
| Sep 30, 2025 | -145.73 Mn |
| Jun 30, 2025 | -168.17 Mn |
| Mar 31, 2025 | -165.59 Mn |
| Dec 31, 2024 | -170.79 Mn |
| Sep 30, 2024 | -141.89 Mn |
| Jun 30, 2024 | -170.75 Mn |
| Mar 31, 2024 | -103.08 Mn |
| Dec 31, 2023 | -115.35 Mn |
| Sep 30, 2023 | -96.06 Mn |
| Jun 30, 2023 | -44.99 Mn |
| Mar 31, 2023 | -78.37 Mn |
| Dec 31, 2022 | -75.71 Mn |
| Sep 30, 2022 | -100.08 Mn |
| Jun 30, 2022 | -68.89 Mn |
| Mar 31, 2022 | -59.08 Mn |
| Dec 31, 2021 | -33.26 Mn |